Clinical Trial

Famotidine and Antacids for Treatment of Dyspepsia

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-26; most recent amendment 2026-06-01.
Trial Details
NCT Number NCT06241183
Lead Sponsor Stony Brook University
Conditions Dyspepsia, GERD, Acid Reflux
Enrollment 80 participants
Start Date 2023-11-09
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02